Key facts
- This page summarizes Thomas Insley's Form 4 filing for Dermata Therapeutics, Inc. (DRMA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Aug 2021, 12:40.
Thomas Insley - 17 Aug 2021 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- DRMA
- Reported as of
- 17 Aug 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Aug 2021, 12:40:45 UTC
- Prior SEC filing
- 12 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gerald T. Proehl, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Thomas Insley filed Form 4 for Dermata Therapeutics, Inc. (DRMA) on 17 Aug 2021.
Change
- Previous filing in this sequence was filed on 12 Aug 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DRMA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +4,581
- Change %
- +47%
- Price
- Shares after
- 14,337
- Date
- 17 Aug 2021
- Ownership
- By Insley Family Trust
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DRMA
transaction
Derivative
Series 1d Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -30,910
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Aug 2021
- Ownership
- By Insley Family Trust
- Underlying class
- Common Stock
- Underlying amount
- 4,581
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Series 1d Preferred Stock converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.
Footnote F2
Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.